An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea

• Status: Unknown status
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This 4-arm Phase 2 vehicle-controlled study is designed to assess the safety and efficacy of PDI-320, and the individual components, in adult subjects with rosacea.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: PreCision Dermatology, Inc.

Criteria

Inclusion Criteria:

• Subject has moderate to severe papulopustular rosacea and at least mild erythema and mild telangiectasia.

• Subject is willing and able to apply the test article(s) as directed, comply with study instructions and commit to all follow-up visits for the duration of the study.

• If subject is a woman of childbearing potential, she must have a negative urine pregnancy test and agree to use an effective form of birth control for the duration of the study.

Exclusion Criteria:

• Subject is pregnant, lactating or is planning to become pregnant during the study.

• Subject has any other active dermatological condition on the face that may interfere with the conduct of the study.

• Subject has used systemic immunosuppressants within 30 days prior to study start.

• Subject has used systemic retinoids within 6 months prior to study start.

• Subject has used any topical rosacea therapy within 14 days prior to study start.

• Subject has had laser or light therapy on the face within 3 months of study start.

• Subject is currently enrolled in an investigational drug or device study.

• Subject has used an investigational drug or investigational device treatment within 30 days prior to first application of the test article.

• Subject has used vasodilators or adrenergic blocking agents within 6 weeks of study start (except subjects on stable dose for greater than 3 months).

• Subject has active ocular rosacea and/or blepharitis/meibomianitis requiring treatment by an ophthalmologist.

• Subject has previously failed to have improvement of rosacea with appropriate use of systemic tetracycline family of antibiotics or use of the components of PDI-320.